- The USPTO issued a patent for BEAT’s 12-lead electrocardiogram (“ECG”) patch monitor for detection of ACS and cardiac arrhythmia
- HeartBeam has developed the only 3D-vector ECG platform for heart-attack detection anytime, anywhere
- BEAT’s patch technology could have a disruptive effect on the ECG patch market with its ischemia detection capability
News about heart attacks and other life-threatening cardiovascular issues is alarming. Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States (https://ibn.fm/FN4BR), and recent reports suggest that COVID-19 may cause heart problems (https://ibn.fm/7QAky) and that the incidence of heart attacks in people under age 40 is increasing (https://ibn.fm/lFzjh). Many companies are working to provide support for this growing problem, including HeartBeam (NASDAQ: BEAT), a cardiac technology company that just received a patent for a proprietary device (https://ibn.fm/RA8EP).
According to a recent announcement from the company, the United States Patent and Trademark Office issued a patent for BEAT’s 12-lead electrocardiogram (“ECG”) patch monitor for detection of acute coronary syndrome (“ACS”) and cardiac arrhythmia. The new patent expands on a previously granted patent for a 12-lead ECG patch monitor technology.
HeartBeam, a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart-attack detection anytime, anywhere, noted that the patent opens a pathway to a disruptive ischemia and arrhythmia detection ECG patch product. In addition, the innovation builds on HeartBeam’s growing intellectual property portfolio that could enable 12-lead ECG diagnostics outside of a medical setting.
“This patent provides additional intellectual property protection for our breakthrough ECG patch technology, offering 12-lead ECG capability in the form of a simple patch that is similar in size and shape to existing single-lead ECG patch monitors in the market today,” said HeartBeam CEO and founder Branislav Vajdic, PhD. “Our 12-lead ECG patch technology offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care and could have a disruptive effect on the ECG patch market with its ischemia detection capability.”
Currently, the ECG patch monitor market is limited to detecting arrhythmias using single-lead ECG devices. HeartBeam’s technology uses a synthesized 12-lead ECG that can aid physicians in both arrhythmia detection and ACS diagnosis, including myocardial infarction (heart attack) and angina. According to the company, the new patent follows HeartBeam’s already-granted core patents for remote detection of heart attacks. “The issued patch patents significantly increase HeartBeam’s intellectual property footprint,” the company stated. “And they further widen the impact HeartBeam’s technology could have on cardiac patients and their physicians.”
The announcement noted that ECG monitors available today are primarily used for detection of abnormal heart rhythms associated with atrial fibrillation or syncope. According to Martin Burke, DO, FACC, a cardiac electrophysiologist and chief scientific officer of the CorVita Science Foundation, “a 12-lead ECG patch would provide additional information to aid in diagnosing conditions such as ACS or more specific arrhythmias that current single-lead patches cannot accurately detect.”
HeartBeam’s exclusive platform applies a suite of proprietary algorithms to simplify vector electrocardiography. The platform can quickly and easily identify whether symptoms may stem from a heart attack, potentially enabling care to be accurately identified and expedited.
The company currently has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo(TM) is the only credit-card-sized, 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system designed to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the USA or other geographies.
For more information, visit the company’s website at www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
